Global Fabry Disease Treatment Market 2025 – 2034

Reports Description

As per the current market research conducted by the CMI Team, the Global Fabry Disease Treatment Market is expected to record a CAGR of 9.8% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 3.10 Billion. By 2034, the valuation is anticipated to reach USD 7.02 Billion.

To learn more about this report - request a sample report PDF

Fabry Disease Treatment Market Overview

An uncommon hereditary disorder, fabry disease can strike many organs including the kidneys, brain, heart, and skin. Among various conditions known as lysosomal storage diseases is Fabry disease. The genetic mutation causing Fabry disease disturbs the activity of an enzyme called sphingolipids, which breaks down macromolecules, therefore accumulating these compounds in the walls of blood vessels and organs.

It is X-linked in inheritance. Though genetic testing is sometimes used, especially in women, fabry disease is sometimes identified with a blood test assessing the activity of the faulty enzyme, alpha-galactosidase. The organs afflicted by Fabry disease determine the course of treatment; hence, the fundamental cause can be resolved by substituting the missing enzyme.

• According to the US official website National Library of Medicine, fabry disease affects an estimated 1 in 1,000 to 9,000 people. Milder, late-onset forms of the disorder are probably more common than the classic, severe form.

Fabry Disease Treatment Market Drivers

Growing Demand For Therapeutic Treatments Drives The Market Growth

In recent years, new medications and treatments that can either treat the basic cause of the disease or reduce its symptoms have greatly increase the options for treating Fabry diseases. While enzyme replacement therapy (ERT) can offer synthetic enzymes to replace missing ones, chaperone therapy can increase the activity of the surviving enzymes.

These drugs can increase organ performance and results even while they help to lower the accumulation of toxic lipids in tissues and cells. An uncommon, progressive hereditary illness, this one can drastically lower life expectancy and lead to ideal issues. To increase their quality of life and stop organ failure or damage, patients and their families look for quick, efficient treatments. These factors help the Fabry treatment industry to grow.

Increasing Clinical Trials Offer a Potential Opportunity For The Industry Development

The growing number of clinical trials in the fabry disease industry offers a potential opportunity for market expansion over the analysis period.

For instance, in October 2024, the clinical trial results of the Phase 3 BRIGHT study of ELFABRIO® (pegunigalsidase alfa-iwxj) 2 mg/kg administered every four weeks for 52 weeks in adult patients with Fabry disease who were previously treated with agalsidase alfa or beta administered every two weeks were published by Chiesi Global Rare Diseases.

ELFABRIO is prescribed at a dose of 1 mg/kg every two weeks. The FDA has not authorized the investigational ELFABRIO 2 mg/kg dosage schedule, which is given every four weeks.

Fabry Disease Treatment Market Challenge

High Cost Of Treatment

The substantial expenses of treating Fabry disease can impede the growth of the market by restricting patients' access to and affordability of the present medications. Enzyme replacement therapy (ERT), injectable synthetic enzymes replacing the absent or damaged enzymes in the bloodstream, is the pillar of therapeutic options for Fabry disease.

The expensive and resource-intensive ERT process needs specialized fabrication, storage, and delivery. According to estimates, ERT for Americans with Fabry disease pays on average, USD 340,000 yearly. The availability and accessibility of medications and therapies across various countries and areas limit even more the alternatives for treating Fabry disease.

Patients may find it difficult to locate specific Fabry disease treatments and medications in various marketplaces since insurance or regulatory bodies may not approve or reimburse some of them.

Fabry Disease Treatment Market Segmentation Analysis

By Treatment:

The Enzyme Replacement Therapy (ERT) segment is expected to dominate the market. The segment's dominance is being driven by the strong sales of Fabrazyme and Replagal as well as the potential approval of exciting pipeline medications.

However, the advent of novel, efficacious therapy alternatives, such gene therapies, will be necessary to significantly improve patient benefits. When it comes to treating illnesses, enzyme replacement therapy is the highest standard.

Besides, the Substrate Reduction Therapy (SRT) segment is growing at a rapid rate. By lowering the synthesis of glycosphingolipids, SRT seeks to decrease the buildup of substrates within cells.

This method provides an alternative to enzyme replacement therapy (ERT), which may help with issues including immunological responses and intravenous delivery, thereby driving the segment growth.

By Route of Administration:

The intravenous route segment is expected to dominate the market. Its connection to Enzyme Replacement Therapy (ERT) is the main cause of this. In order to replace the missing or dysfunctional enzymes that are a feature of Fabry disease, ERT entails injecting artificial enzymes straight into the bloodstream. By efficiently delivering therapeutic enzymes to target cells, this approach successfully lowers substrate buildup and reduces the symptoms of disease.

Besides, the oral route segment is growing at a rapid rate. Since oral drugs don't require frequent hospital visits for intravenous infusions, patients can manage their therapy at home. More effective illness management results from improved adherence to recommended regimens brought forth by this convenience.

By Distribution Channel:

The hospital pharmacy segment is expected to dominate the market. Because hospital pharmacies are in charge of giving patients pharmaceutical prescriptions during hospital-based inpatient or outpatient therapy, they are primary distribution channels for drugs used to treat Fabry disease, including injectable and oral therapies.

Besides, the retail pharmacy segment is growing at a rapid rate. Retail pharmacies frequently work closely with medical professionals to efficiently manage and track patient results. By working together, the effectiveness of the treatment is maximized and any negative effects or complications are swiftly treated.

Report Scope

Fabry Disease Treatment Market Regional Analysis

North America is projected to dominate the fabry disease treatment market. The market expansion in the region is owing to the presence of advanced healthcare infrastructure. Timely diagnosis and efficient treatment of Fabry disease are made possible by the existence of reputable medical facilities.

Additionally, programs like the United States' yearly Fabry Disease Awareness Month have improved professional and public knowledge of the illness, resulting in earlier diagnosis and treatment.

However, the Asia Pacific is growing at a significant pace in the global fabry disease treatment industry. The demand for products and services related to Fabry disease treatment is anticipated to rise due to the region's huge population, growing urbanization, and rising disposable income.

Fabry Disease Treatment Market Recent Development

The fabry disease treatment industry adopted several strategies which include product launches, acquisitions, collaboration, expansion and others. Some of the company strategies include:

• In December 2024, FDA officials granted orphan drug designation to EXG110 (Exegenesis Bio), a novel gene therapy being investigated for use in Fabry disease.

• In May 2024, the American Kidney Fund (AKF) announced an education and awareness campaign to increase visibility of Fabry disease. The campaign will include encouraging patients with chronic kidney disease (CKD) with an unknown underlying cause to get tested for Fabry disease. The campaign is being funded through a partnership with Sanofi Genzyme, a company working to support the rare disease community for more than 35 years.

The increasing approvals and rising collaboration among the key players are the strategies that have expanded the market presence of the company in the fabry disease treatment industry and gained its competitive edge.

List of the prominent players in the Fabry Disease Treatment Market:

• Sanofi S.A.
• Shire PIc.
• Amicus Therapeutics Inc.
• ISU Abxis Co Ltd.
• JCR Pharmaceuticals Co Ltd.
• Protalix Biotherapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Avrobio Inc.
• Takeda Pharmkceutical Co Ltd.
• Chiesi Farmaceutici SpA
• Freeline Therapeutics Holdings PLC
• Yuhan Corp
• MOP Therapeutics
• Others

The Fabry Disease Treatment Market is segmented as follows:

By Treatment

• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Others

By Route of Administration

• Intravenous Route
• Oral Route

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America